Influenza in Birds
Recent clinical, regulatory, research and industry developments relating to this disease.
The immune system of chicken and its response to H9N2 avian influenza virus.
Creating resistance to avian influenza infection through genome editing of the ANP32 gene family.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 6 clinical trials expected to report results, the earliest in Q3 2026.
- Q3 2026EVax-3: Human Upper and Lower Airway Mucosal Immune Response to FluMist Vaccination
- Q1 2027Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart - A Multi-Center Non-Inferiority Placebo-Controlled Observer-Blinded Phase 2 Randomized Controlled Trial
- Q2 2027A Phase III, Multicenter, Double-blind, Randomized, Parallel-group Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate Compared to Benegrip® in Improving Symptoms of the Common Cold and Flu in Adult Participants
- Q2 2027Comparison of Immunogenicity of Different Influenza Vaccines in Patients With Hematologic Malignancies
- Q4 2028The Effects of Woodsmoke Exposure on Nasal Immune Responses to Influenza Infection in Normal Human Volunteers
Clinical MilestonesView all 13Hide
- 2026-06-16A Phase III, Multicenter, Double-blind, Randomized, Parallel-group Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate Compared to Benegrip® in Improving Symptoms of the Common Cold and Flu in Adult ParticipantsResults expected Q2 2027
- 2026-05-15The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study - a Randomized Controlled TrialResults expected Q4 2030
- 2026-04-30The Effects of Woodsmoke Exposure on Nasal Immune Responses to Influenza Infection in Normal Human VolunteersResults expected Q4 2028
- 2026-03-24Comparison of Immunogenicity of Different Influenza Vaccines in Patients With Hematologic MalignanciesResults expected Q2 2027
- 2026-01-16Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart - A Multi-Center Non-Inferiority Placebo-Controlled Observer-Blinded Phase 2 Randomized Controlled TrialResults expected Q1 2027
- 2026-06-15A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad Quadrivalent Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of AgeCompleted
- 2026-01-22Live Attenuated Influenza Vaccine as a Nasal Model for Influenza InfectionCompleted
- 2025-11-17A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adults ≥50 Years of AgeCompleted
- 2025-08-26A Multicenter, Randomized, Parallel-group, Double-blind, Comparative Trial of the Superiority of Paracetamol 500mg/Fexofenadine 60mg/Phenylephrine 20mg Fixed-dose Combination Versus Placebo in the Symptomatic Treatment of Flu and ColdCompleted
- 2025-08-21A Phase 3, Randomized, Observer-blind, Active-controlled, Case-driven Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared With a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of AgeCompleted
- 2026-06-16ClinicalA Phase III, Multicenter, Double-blind, Randomized, Parallel-group Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate Compared to Benegrip® in Improving Symptoms of the Common Cold and Flu in Adult ParticipantsResults expected Q2 2027
- 2026-06-15ClinicalA Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad Quadrivalent Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of AgeCompleted
- 2026-05-19ClinicalRandomized Controlled Trial, Double Blind, Phase III, to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among Health Care Personnel (EDUCATE)Results posted
- 2026-05-17ClinicalA Phase 3, Randomized, Observer-Blinded, Study to Compare the Safety and Immunogenicity of 3 Lots of SARS-CoV-2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix M™ Adjuvant in Participants ≥ 65 Years of AgeWithdrawn
- 2026-05-15ClinicalThe Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study - a Randomized Controlled TrialResults expected Q4 2030
- 2026-04-30ClinicalThe Effects of Woodsmoke Exposure on Nasal Immune Responses to Influenza Infection in Normal Human VolunteersResults expected Q4 2028
- 2026-03-24ClinicalComparison of Immunogenicity of Different Influenza Vaccines in Patients With Hematologic MalignanciesResults expected Q2 2027
- 2026-01-22ClinicalLive Attenuated Influenza Vaccine as a Nasal Model for Influenza InfectionCompleted
- 2026-01-16ClinicalImmunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart - A Multi-Center Non-Inferiority Placebo-Controlled Observer-Blinded Phase 2 Randomized Controlled TrialResults expected Q1 2027
- 2025-11-17ClinicalA Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adults ≥50 Years of AgeCompleted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes3
- Influenza in Birds2
- Influenza A virus1
- Influenza A Virus, H9N2 Subtype1
Leading journals2
- Nature communications1
- The veterinary quarterly1
Leading researchers8
- Barclay WS1
- Bialy D1
- Brown JC1
- Campbell C1
- Goldhill DH1
- Idoko-Akoh A1
- Liu X1
- Long JS1
Affiliations (unnormalised)6
- Animal Infectious Disease Laboratory1
- Imperial College London1
- Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonosis1
- Jiangsu Key Laboratory of Zoonosis1
- National Institute for Biological Standards and Control1
- Royal Veterinary College1
Reference
Authoritative identity, definition & identifiers.
Infection of domestic and wild fowl and other BIRDS with INFLUENZA A VIRUS. Avian influenza usually does not sicken birds, but can be highly pathogenic and fatal in domestic POULTRY.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.